Aperus Pharma Ltd. Was set up by NAVIGATOR together with AVIDIN, a biotech company engaged in the development of cure for Alzheimer’s disease. The primary task of NAVIGATOR is the management of the company and the coordination of negotiations with possible investors.

AVIDIN Ltd. has been searching for the cure for Alzheimer’s disease since 2009. The company discovered its drug candidate (Q134R-K) during its molecular-level biological and chemical development projects, which was patented worldwide under the name Kinolol. NAVIGATOR joined the project in 2017, in which it became a venture capital investor and advisor in the project.

The Phase I tests were successfully carried out and were closed on 15 December 2017. Q134R-K provides not only symptomatic treatment for the disease, but due to its original mechanisms it may even be able to stop the further development of the disease and improve the brain functions of patients by influencing the background processes behind the Alzheimer’s disease.

It was proven that the drug candidate is absorbed well by the digestive system and is safe as no serious side effects appeared during testing.

In the framework of the successful tender, with the involvement of large companies from all over the world, the mechanism of the drug candidate was successfully revealed, which shed light to the effects that can stop the further development of the disease. The revolutionary mechanism of the Q-134R-K molecule had brought the attention of the scientific world. The processes which are intended to protect the neurons is being tested in one of the seven centres in the USA designed to research Alzheimer’s, at Kentucky University, where a well-known researcher of the area undertakes the activity with financial support from the Alzheimer’s Drug Discovery Foundation (ADDF). He presented the first results on the 13^th International Conference on Alzheimer’s and Parkinson’s Disease (AD/AP) in 2017.

The Alzheimer is primarily the disease of the elder generations, a progressive, degenerative, neurological diseases, the most common form of dementia. It is characterized by the gradual loss of memory and cognitive functions, which can evolve to a level where it makes everyday activities a challenge. In the final phase the patient becomes incapacitated and is basically tied to bed. Currently about 44 million people suffer from Alzheimer’s Disease in the world, and according to the statistics this number doubles every 20 years. Alzheimer is among the most serious and costly diseases. In 2016 in the United States alone the treatment of the 5.3 million patients costs 236 billion dollars. There is no such medication on the market which would be able to prevent or stop the disease or postponing its harsh symptoms.